Academic Journal
أعرض في EDS

Entrectinib—A SARS-CoV-2 Inhibitor in Human Lung Tissue (HLT) Cells

التفاصيل البيبلوغرافية
العنوان: Entrectinib—A SARS-CoV-2 Inhibitor in Human Lung Tissue (HLT) Cells
المؤلفون: Peralta-Garcia, Alejandro, Torrens-Fontanals, Mariona, Stepniewski, Tomasz Maciej, Grau Exposito, Judit, Perea Pérez, David, Ayinampudi, Vikram, Buzón Gómez, María José, Genesca Ferrer, Meritxell
المساهمون: Institut Català de la Salut, Peralta-Garcia A, Torrens-Fontanals M Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences, Hospital del Mar Medical Research Institute (IMIM), Pompeu Fabra University (UPF), 08003 Barcelona, Spain. Stepniewski TM Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences, Hospital del Mar Medical Research Institute (IMIM), Pompeu Fabra University (UPF), 08003 Barcelona, Spain. InterAx Biotech AG, PARK InnovAARE, 5234 Villigen, Switzerland. Grau-Expósito J, Perea D, Buzón MJ, Genescà M Servei de Malalties Infeccioses, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Ayinampudi V InterAx Biotech AG, PARK InnovAARE, 5234 Villigen, Switzerland, Vall d'Hebron Barcelona Hospital Campus
المصدر: Scientia
بيانات النشر: MDPI
سنة النشر: 2021
مصطلحات موضوعية: Medicaments antivírics, COVID-19 (Malaltia), Medicaments - Ús, CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral Agents, Other subheadings::Other subheadings::/pharmacology, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Drug Development::Drug Repositioning, DISEASES::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections, COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antiinfecciosos::antivíricos, Otros calificadores::Otros calificadores::/farmacología, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::desarrollo de medicamentos::nuevas indicaciones de medicamentos, ENFERMEDADES::virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus
الوصف: COVID-19; Drug repurposing; Viral cell entry assays ; COVID-19; Reutilización de medicamentos; Ensayos de entrada de células virales ; COVID-19; Reutilització de medicaments; Assajos d'entrada de cèl·lules virals ; Since the start of the COVID-19 outbreak, pharmaceutical companies and research groups have focused on the development of vaccines and antiviral drugs against SARS-CoV-2. Here, we apply a drug repurposing strategy to identify drug candidates that are able to block the entrance of the virus into human cells. By combining virtual screening with in vitro pseudovirus assays and antiviral assays in Human Lung Tissue (HLT) cells, we identify entrectinib as a potential antiviral drug. ; This research was funded by the Spanish Ministry of Science, Innovation, and Universities (FPU16/01209 to M.T.-F.); the Health department of the Government of Catalonia (DGRIS 3_9 to A.P.G. and J.S. and DGRIS 1_5 to M.J.B. and M.G.).
نوع الوثيقة: article in journal/newspaper
وصف الملف: application/pdf
اللغة: English
تدمد: 1422-0067
Relation: International Journal of Molecular Sciences;22(24); https://doi.org/10.3390/ijms222413592; Peralta-Garcia A, Torrens-Fontanals M, Stepniewski TM, Grau-Expósito J, Perea D, Ayinampudi V, et al. Entrectinib—A SARS-CoV-2 Inhibitor in Human Lung Tissue (HLT) Cells. Int J Mol Sci. 2021 Dec;22(24):13592.; https://hdl.handle.net/11351/7684; 000737887800001
DOI: 10.3390/ijms222413592
الاتاحة: https://hdl.handle.net/11351/7684
https://doi.org/10.3390/ijms222413592
Rights: Attribution 4.0 International ; http://creativecommons.org/licenses/by/4.0/ ; info:eu-repo/semantics/openAccess
رقم الانضمام: edsbas.39E2B176
قاعدة البيانات: BASE
الوصف
تدمد:14220067
DOI:10.3390/ijms222413592